Characteristics of patients in FL discovery and validation cohorts
| Characteristic . | Discovery cohort (n = 38) . | Validation cohort (n = 128) . |
|---|---|---|
| Age (median, range) | 63 (27-84) | 64 (26-91) |
| Sex, male n (%) | 20 (51%) | 55 (43%) |
| Stage | ||
| 1 | 16 (44%) | 18 (14%) |
| 2 | 16 (43.25%) | 27 (21%) |
| 3 | 6 (16.25%) | 23 (18%) |
| 4 | 0 (0%) | 61 (47%) |
| B symptoms (present) | 7 | 13 |
| LDH (elevated) | 3 | 11 |
| FLIPI | ||
| 0-1 | 14 (37%) | 53 (41%) |
| 2 | 11 (29%) | 53 (41%) |
| 3-4 | 13 (34%) | 22 (17%) |
| Unknown | 0 (0%) | 1 (1%) |
| Initial therapy | Therapy prior to sample | Initial therapy |
| Observation | 23 (60.5%) | 59 (46%) |
| Chemotherapy | 8 (21%) | 36 (28%) |
| Chemotherapy plus rituximab | 2 (5.3%) | 3 (2%) |
| Rituximab | 0 (0%) | 3 (2%) |
| RT | 0 (0%) | 16 (12%) |
| RT plus chemotherapy | 5 (13.2) | 2 (2%) |
| Surgical resection | 0 (0%) | 10 (8%) |
| Characteristic . | Discovery cohort (n = 38) . | Validation cohort (n = 128) . |
|---|---|---|
| Age (median, range) | 63 (27-84) | 64 (26-91) |
| Sex, male n (%) | 20 (51%) | 55 (43%) |
| Stage | ||
| 1 | 16 (44%) | 18 (14%) |
| 2 | 16 (43.25%) | 27 (21%) |
| 3 | 6 (16.25%) | 23 (18%) |
| 4 | 0 (0%) | 61 (47%) |
| B symptoms (present) | 7 | 13 |
| LDH (elevated) | 3 | 11 |
| FLIPI | ||
| 0-1 | 14 (37%) | 53 (41%) |
| 2 | 11 (29%) | 53 (41%) |
| 3-4 | 13 (34%) | 22 (17%) |
| Unknown | 0 (0%) | 1 (1%) |
| Initial therapy | Therapy prior to sample | Initial therapy |
| Observation | 23 (60.5%) | 59 (46%) |
| Chemotherapy | 8 (21%) | 36 (28%) |
| Chemotherapy plus rituximab | 2 (5.3%) | 3 (2%) |
| Rituximab | 0 (0%) | 3 (2%) |
| RT | 0 (0%) | 16 (12%) |
| RT plus chemotherapy | 5 (13.2) | 2 (2%) |
| Surgical resection | 0 (0%) | 10 (8%) |
RT, radiation therapy; LDH, lactate dehydrogenase.